

ASX RELEASE (21 MAY 2020)

THC Global's medicinal cannabis product now available via prescription in Australia

Investment Highlights:

- THC Global's Australian-produced full-spectrum CBD medicine now available under Australia's Special Access Schemes
- Full-spectrum medicines are in high demand for prescribers and patients seeking benefit of minor cannabinoids, terpenes and flavonoids which may provide different therapeutic outcomes
- Product manufactured from cannabis plant material cultivated at THC Global's Bundaberg facility
- THC Global's CanndeoCare team supporting doctors and pharmacies with guidance and product information
- New Canndeo medicines to be made available to Tetra Health prescriber network
- Delivering an affordable and accessible high-quality TGA GMP medicine to Australian patients

THC Global Group Limited (**THC Global** or the **Company**) (ASX:THC) is pleased to confirm that the Company's first Australian-produced medicinal cannabis product is now available for prescription to Australian patients under Australia's existing Special Access Schemes.

The first product, launched yesterday, is a full-spectrum cannabidiol (CBD) medicine. Full-spectrum medicines are highly sought after by both patients and prescribers as they include minor cannabinoids, terpenes and flavonoids that may provide different therapeutic outcomes for patients than CBD medicine formulated from isolate.

Under the Canndeo brand, this first product been produced entirely in Australia using cannabis sourced from the Company's Bundaberg cultivation facility, and manufactured at the Company's Southport Facility which is fully TGA GMP licenced, enabling future export of these products as EU GMP medicines.

The Company's medical and clinical affairs team, CanndeoCare, will support doctors, pharmacists, and other healthcare professionals in the prescription of these medicines. They are equipped to provide expert advice and guidance on the technical and medical aspects of medicinal cannabis patient management. Additionally, Tetra Health, the Company's recently acquired clinic network [ASX Announcement: 12 May 2020], will enable its network of referring and prescribing physicians to access this new medicine.

The Canndeo brand is the flagship brand for THC Global and brings together Australian production, full pharmaceutical quality and affordability. The Company anticipates that the combination of quality and affordability will be of interest to Australians for whom affordability has been a barrier, and those who have been accessing high cost imported medicinal cannabis to date.

THC Global will continue the progressive roll-out of its Australian-produced TGA GMP medicines range over the coming months for both Australian patients and the global export market.



Above: Canndeo's CBD medicine now available for prescription



THC Global CEO, Ken Charteris said: “Getting our wholly Australian medicinal cannabis product to be available for prescribing by Australian doctors is a real milestone for THC Global. We look forward to increasing the number of Australian patients able to access medicinal cannabis medicines by providing an affordable medicine and supporting both patients and prescribers in the legal and safe use of these products. We’re on track to continue the expansion of our affordable and accessible TGA GMP medicines range through 2020.”

For further information, please contact:



Ken Charteris
Chief Executive Officer
e: ceo@thc.global

Sonny Didugu & Jarrod White
Joint Company Secretaries
e: corporate@thc.global
p: +61 2 8088 4760

The Capital Network
Julia Maguire
e: julia@thecapitalnetwork.com.au
p: + 61 2 8999 3699

ASX release authorised by THC Global’s Management Committee – the Chairman, Deputy Chairman, and CEO.

THC Global Group Limited (ASX: THC) thc.global

THC Global is a diversified global cannabis company with primary operations in Australia and Canada. THC Global is the first ASX listed entity to fully own and operate end to end commercial medicinal cannabis production facilities under Australia’s cannabis regulations. THC Global’s Southport Facility is one of the largest pharmaceutical GMP cannabis manufacturing facilities in the world. THC Global also owns and operates Crystal Mountain, a fast growing hydroponics equipment and supplies wholesaler and retailer servicing the rapidly expanding cannabis sector in North America and Europe.

For prospective patients or healthcare professionals seeking more information on medicinal cannabis, please visit: canndeocare.com and tetrahealth.com.au.